rational pharmacological approaches for cognitive dysfunction and depression in parkinson’s disease
Clicks: 180
ID: 244219
2015
Article Quality & Performance Metrics
Overall Quality
Improving Quality
0.0
/100
Combines engagement data with AI-assessed academic quality
Reader Engagement
Emerging Content
0.9
/100
3 views
3 readers
Trending
AI Quality Assessment
Not analyzed
Abstract
Parkinson´s disease (PD) is not a single entity but rather a heterogeneous neurodegenerative disorder. The present study aims to conduct a critical systematic review of the literature to describe the main pharmacological treatment strategies to treat cognitive dysfunction and major depressive disorder in PD patients. We performed a search of articles cited in PubMed from 2004 to 2014 using the following MeSH terms (Medical subject headings) parkinson disease; Delirium, Dementia, Amnestic, Cognitive disorders and parkinson disease; depression; depressive disorder major; drug therapy. We found a total of 71 studies related to pharmacological treatment in cognitive dysfunction and 279 studies for pharmacological treatment in major depressive disorder. After fulfillment of all the inclusion and exclusion criteria, 13 articles remained for cognitive dysfunction and 11 for major depressive disorder, which are presented and discussed in this study. Further research into non-motor symptoms of PD may provide insights into mechanisms of neurodegeneration, and provide better quality of life by using rational drugs.Reference Key |
esandoval-rincn2015frontiersrational
Use this key to autocite in the manuscript while using
SciMatic Manuscript Manager or Thesis Manager
|
---|---|
Authors | ;Maritza eSandoval-Rincón;Michel eSáenz-Farret;Michel eSáenz-Farret;Adán eMiguel-Puga;Federico eMicheli;Oscar eArias-Carrión;Oscar eArias-Carrión |
Journal | journal of photochemistry and photobiology a: chemistry |
Year | 2015 |
DOI | 10.3389/fneur.2015.00071 |
URL | |
Keywords |
Citations
No citations found. To add a citation, contact the admin at info@scimatic.org
Comments
No comments yet. Be the first to comment on this article.